Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

7 clinical studies listed.

Filters:

Vulvovaginal Candidiasis

Tundra lists 7 Vulvovaginal Candidiasis clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT05753813

Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome

This project aims to investigate if the contraceptive method, Phexxi, causes changes to the composition of the vaginal microbiome. The investigators hypothesize that regular use of Phexxi will cause increased colonization of lactic acid-producing lactobacilli, which could have positive effects in the way of preventing recurrent episodes of BV and candida infections.

Gender: FEMALE

Ages: 18 Years - 54 Years

Updated: 2026-02-20

1 state

Bacterial Vaginosis
Vulvovaginal Candidiasis
NOT YET RECRUITING

NCT07044947

Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis(VVC)

Oteseconazole is a novel, oral, highly selective inhibitor of fungal CYP51. Oteseconazole showed statistically significant and clinically meaningful treatment of severe VVC and was generally tolerated. The trial is a national multi-center, non-interventional observational real-world study, aiming to evaluate the effecacy and safety of oteseconazole in the treatment of patients with VVC. This study will include patients with severe vulvovaginal candidiasis (SVVC) . It is divided into prospective and retrospective parts.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2025-07-01

Vulvovaginal Candidiasis
RECRUITING

NCT06480604

Effect of a Multi-strain Probiotic on Recurrent Vulvovaginal Candidiasis

This study evaluates the effect of a multi-strain probiotic on the risk of recurrence and severity of symptoms in females with recurrent vulvovaginal candidiasis (R-VVC).

Gender: FEMALE

Ages: 18 Years - 50 Years

Updated: 2024-11-07

2 states

Vulvovaginal Candidiasis
RECRUITING

NCT05908682

Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes

This is an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age.

Gender: FEMALE

Ages: 0 Years - Any

Updated: 2024-07-17

1 state

Vulvovaginal Candidiasis
Candida Infection
Vaginal Candidiasis
NOT YET RECRUITING

NCT06450990

Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection

The purpose of this clinical trial is to investigate the clinical efficacy and safety of a Live Biotherapeutic Product (BGY-1601-VT) intended as a first line of treatment in cases of acute vaginal infection without upfront microbiological confirmed diagnosis

Gender: FEMALE

Ages: 18 Years - 50 Years

Updated: 2024-06-12

Bacterial Vaginosis
Vulvovaginal Candidiasis
RECRUITING

NCT06397248

DeVEnIR: Defining Vulvovaginal Candidiasis - Elements of Infection and Remedy

Female-specific health conditions are underrepresented in research. The taboo felt by women to talk about intimate wellbeing is fed by this gender gap in scientific knowledge. This project aims to meet these needs by studying one of the most prevalent female-specific infections, vulvovaginal candidiasis (VVC), and paving the way towards its efficient diagnosis and treatment. About 70% of women worldwide suffer from vaginal candidiasis at least once in their life. An episode of this fungal infection is accompanied by a burning sensation, pain, and reduced mental well-being. Some women (about 5%) encounter such infections at least four times a year, referring to recurrent(R) VVC. The design of efficient diagnostic and therapeutic strategies for (R)VVC is hindered by a knowledge gap surrounding vaginal health. To meet the absolute need for more information, this project will characterize the role of the microbiome, metabolome, immune system, and pathogen characteristics in (R)VVC. To this end, a large sampling platform of women with/without VVC will be established in this project. The researchers will identify the most important and clinically relevant microorganisms, metabolites, and immune factors in VVC pathogenesis. VVC models will be developed and optimized, which will be used to validate the causality of the correlations identified in the cohort. Identified correlations will be proposed as biomarkers, and microbes, metabolites, and combinations, which effectively lower the pathogenicity of Candida species, will be further investigated for therapeutic potential. State-of-the-art tools and know-how of the researchers will allow the unraveling of the involved molecular pathways and elucidate how these can be exploited to optimize therapeutic efficacy. Finally, the knowledge gathered in this project will be used to improve the literacy of women on VVC using platforms established by the researchers as well as novel tools to be developed in this project.

Gender: FEMALE

Ages: 18 Years - 50 Years

Updated: 2024-05-28

1 state

Vulvovaginal Candidiasis
RECRUITING

NCT05079711

Comparative Performance of a Vaginal Yeast Test

The purpose of this study is to establish lay user performance criteria for the SavvyCheck Vaginal Yeast Test in comparison to standard vaginal yeast culture and identification method for Candida (the Reference Method). Polymerase chain reaction (PCR) and sequencing of fungi will be used as an aid to explain the nature of the discrepancy in the case of discordant results between the lay user-performed SavvyCheck Vaginal Yeast Test and standard vaginal yeast culture and identification method for Candida.

Gender: FEMALE

Ages: 18 Years - Any

Updated: 2024-05-16

2 states

Vulvovaginal Candidiasis